ANDOVER, Mass.--(BUSINESS WIRE)-- Today, Formatech, Inc. announces the selection of RegeneRx Biopharmaceuticals, Inc.’s therapeutic product candidate RGN-352 as the next Fillanthropy™ Program candidate. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in clinical trials.
RGN-352 is an injectable formulation of a novel therapeutic peptide known as Thymosin Beta 4, or Tβ4, for systemic delivery to treat cardiovascular diseases, central nervous system diseases and other medical indications that can be treated by systemic administration. Recent preclinical research showed that Tβ4 significantly improved neurologic functional recovery in mice with experimental autoimmune encephalomyelitis, or EAE. This model is widely used for the study of multiple sclerosis, or MS. A debilitating disease with currently no cure, MS affects approximately 2.5 million persons worldwide. Based on the preclinical research, RegeneRx intends to supply RGN-352 in support of a Phase 1/2 clinical trial to evaluate its potential to treat patients with MS, which is proposed to be conducted at a major U.S. medical center under a physician-sponsored investigational new drug application.
“We are grateful that we can to contribute our services in an effort to find a new treatment for those afflicted with MS,” said Jeffrey Bernard, Director of Business Development at Formatech. “We are hopeful that RGN-352 will improve the quality of life for those suffering from this disease.”
About the Fillanthropy Program
Each month, Formatech will select a company to donate the services required to aseptically fill and finish one lot of drug product entering human clinical trials. We consider both the product’s potential therapeutic benefit and the financial need of the applicant. To apply, companies are encouraged to contact Jeffrey Bernard at 978-725-9077 x3164 or [email protected].
About Formatech
Formatech is a contract service provider that delivers unique solutions to bio/pharmaceutical product development and manufacturing challenges. To learn more about the company and its services, visit www.formatech.com.
Formatech’s mission is to “Help make new drugs happen at the speed of science.”
CONTACT:
Formatech, Inc.
Jeffrey Bernard, 877-853-KEYS or 978-725-9077 Ext. 3164
Director of Business Development
[email protected]
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Other Consumer Health Biotechnology Clinical Trials Infectious Diseases Oncology Pharmaceutical Other Health Philanthropy Research Other Philanthropy FDA Consumer Science
MEDIA:
| Logo |